SCHEMBL4922407

SCHEMBL4922407

CCCc1nn(CC)c2c(=O)n(CCCOc3ccc(SC(C)(C)C(=O)O)cc3)c(C)nc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.34
MAPK14 Q16539 2/20 0.34
PIN1 Q13526 1/20 0.32
PKM P14618 1/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 2/20 0.32
HTT P42858 1/20 0.32
SLC22A12 Q96S37 1/20 0.31
ADORA2B P29275 3/20 0.31
ADORA3 P0DMS8 2/20 0.31
MCL1 Q07820 1/20 0.31
ADORA1 P30542 1/20 0.31
PPARA Q07869 3/20 0.31
PPARG P37231 2/20 0.31
PPARD Q03181 1/20 0.31
MAPT P10636 3/20 0.31
ADRA1A P35348 1/20 0.31
KCNH2 Q12809 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921723 0.96 PKM (0.34) ADORA2AMAPK14PKMLMNASLC22A12
SCHEMBL3842114 0.92 PPARA (0.34) ADORA2AMAPK14ADORA2BPPARAALDH1A1
SCHEMBL3847182 0.92 MAPK14 (0.35) ADORA2AMAPK14PIN1PKMTP53
SCHEMBL4921612 0.92 MAPK14 (0.36) ADORA2AMAPK14PIN1LMNATP53
SCHEMBL4920281 0.88 PKM (0.33) ADORA2AMAPK14PKMLMNAPPARA
SCHEMBL4916708 0.88 PPARA (0.38) ADORA2AMAPK14PKMLMNAPPARA
SCHEMBL3841929 0.88 PPARA (0.36) ADORA2AMAPK14PKMPPARAPPARG
SCHEMBL3839967 0.87 PDE5A (0.37) ADORA2AMAPK14PKMPPARAALDH1A1
SCHEMBL3850195 0.85 PPARA (0.37) ADORA2AMAPK14TP53ADORA2BPPARA
SCHEMBL4922962 0.84 MAPK14 (0.38) ADORA2AMAPK14TP53ADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity PPARA, PPARD, PPARG ADORA2A 421/4885MAPK14 3697/4885PIN1 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.